Europeans OK expanded use of Amgen’s Blincyto
The European Commission approved an expanded use for Amgen’s leukemia therapy Blincyto in treating pediatric patients Aug. 29. Based on results from a study of 93 pediatric patients, the approval allows its use in patients a year old or older with a particular type of relapsed or refractory acute lymphoblastic leukemia. “Historically, children with relapsed Read More →
Read More →
Study results modest for Sienna psoriasis treatment
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Read More →New Ventura County supervisor leaves a legacy in Simi Valley
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Read More →New drugs boost profits at Amgen as two executives leave company
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Read More →MannKind doubles revenues from inhalable insulin Afrezza
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Read More →Teledyne Technologies reports best second quarter results ever
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Read More →Atara Biotherapeutics net losses worse than expected by analysts
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Read More →
Sponsored content:
2015-2016 Giving Guide
